(RTTNews) - Seer, Inc. (SEER), a life sciences company, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:00 p.m. PT / 6:00 p.m. ET.
The financial results for the third quarter ended September 30, 2024, were reported recently.
Seer reported a net loss of $21.3 million, or $0.35 per share, for the third quarter of 2024, compared to a net loss of $21.1 million, or $0.33 per share, in the same period of 2023.
Revenue for the third quarter of 2024 was $4.0 million compared to $4.2 million in the year-ago quarter, which is a 3 percent decrease, primarily driven by lower related party and grant revenue.
Adjusted EBITDA for the third quarter of 2024 was negative $19.8 million, compared to negative $18.8 million for the same period in 2023.
The company repurchased approximately 3.7 million shares of its Class A common stock at an average cost of $1.78 per share during the third quarter, bringing the total shares repurchased to 5.7 million shares as of the end of the third quarter of 2024.
Looking ahead, Seer expects full-year 2024 revenue to range between $13 million and $15 million. Total revenue for the full year 2023 was $16.7 million.
As of September 30, 2024, Seer reported cash, cash equivalents, and investments totaling $312 million.
SEER shares debuted on the Nasdaqglobal marketon December 4, 2020, under the ticker symbol "SEER", priced at $19.00 per share.
SEER closed Thursday's (Jan. 02, 2025) trading at $2.33, up 0.87%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
